PDCD1 and neoplasm: Compared with those of the groups treated with GalNAc–siTACC3 or PD-1 mAb alone, the results of both the subcutaneous and orthotopic tumor models indicated that GalNAc–siTACC3 and PD-1 mAb strikingly inhibited tumor growth (Fig. 7e‒i) and improved OS time (Fig. 7j).